$AQST

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. aqst-20260610 0001398733 false 0001398733 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): J

Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ:AQST) for alleged violations of federal securities laws. The lawsuit claims Aquestive made false and misleading statements about the approval timeline for its Anaphylm NDA, failing to disclose significant human factors risks impacting regulatory approval. Investors who purchased AQST securities between June 16, 2025, and January 8, 2026, are encouraged to join the lawsuit and have until May 4, 2026, to request to be appointed as lead plaintiff.

Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Aquestive Therapeutics, Inc. (AQST) on behalf of investors who purchased securities between June 16, 2025, and January 8, 2026. The lawsuit alleges that Aquestive gave the false impression that its New Drug Application for Anaphylm would be approved by the January 31, 2026 PDUFA date, despite the FDA identifying deficiencies. Investors who suffered losses have until May 4, 2026, to apply to be appointed as lead plaintiff.

The Rosen Law Firm is reminding investors of Aquestive Therapeutics, Inc. (NASDAQ: AQST) who purchased securities between June 16, 2025, and January 8, 2026, about the May 4, 2026, deadline to seek lead plaintiff status in a securities class action lawsuit. The lawsuit alleges that Aquestive made false and misleading statements regarding its New Drug Application for Anaphylm, specifically minimizing the significance of human factors in its product's use. Investors who suffered damages are encouraged to contact the firm.

Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Aquestive Therapeutics, Inc. for investors who purchased securities between June 16, 2025, and January 8, 2026. The lawsuit alleges that Aquestive gave a false impression about the approval of its New Drug Application for Anaphylm, leading to a significant stock price drop after deficiencies were identified by the FDA. Investors who suffered losses have until May 4, 2026, to apply for lead plaintiff in the lawsuit.

Bernstein Liebhard LLP reminds investors of Aquestive Therapeutics, Inc. (AQST) about an upcoming deadline in a securities fraud class action lawsuit. Investors who purchased shares between June 16, 2025, and January 8, 2026, and lost money, are encouraged to contact the firm by May 4, 2026, to discuss their legal options, including serving as lead plaintiff. The lawsuit alleges that Aquestive made misrepresentations regarding its New Drug Application for Anaphylm.

The Pomerantz LLP law firm has announced a class action lawsuit against Aquestive Therapeutics, Inc. (AQST) regarding alleged securities fraud or unlawful business practices. The lawsuit follows Aquestive's stock price drop after the FDA identified deficiencies in its New Drug Application for Anaphylm, delaying its approval indefinitely. Investors who purchased Aquestive securities during the Class Period have until May 4, 2026, to seek appointment as Lead Plaintiff.

Holzer & Holzer, LLC is reminding investors of the upcoming lead plaintiff deadlines in class action lawsuits against REGENXBIO Inc. (RGNX), Franklin BSP Realty Trust, Inc. (FBRT), and Aquestive Therapeutics, Inc. (AQST). Investors who suffered significant losses during specified periods for each company are encouraged to contact the firm to discuss their legal rights. The deadlines to seek appointment as lead plaintiff are April 14, 2026, for RGNX, April 27, 2026, for FBRT, and May 4, 2026, for AQST.

Levi & Korsinsky is alerting investors about a securities fraud lawsuit against Aquestive Therapeutics, Inc. (AQST). The lawsuit alleges that investors who purchased AQST securities between June 16, 2025, and January 8, 2026, suffered significant losses after an analyst slashed the price target due to identified deficiencies in the FDA's review of Anaphylm, which contradicted management's prior assurances. The firm is encouraging affected investors to seek to lead the class action by the May 4, 2026 deadline.

Faruqi & Faruqi, LLP is investigating Aquestive Therapeutics, Inc. (NASDAQ: AQST) after the company's stock plunged approximately 40% due to the FDA identifying deficiencies in its New Drug Application for Anaphylm. The deficiencies prevent discussions of labeling and post-marketing requirements, raising concerns about the application's approvability before the January 31, 2026, PDUFA action date. The firm is encouraging investors who suffered significant losses to contact them to discuss their legal options.